Exelixis, Inc. (NASDAQ:EXEL) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET
Company Participants
Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations
Michael Morrissey - President and Chief Executive Officer
Christopher Senner - Executive Vice President and Chief Financial Officer
P.J. Haley - Executive Vice President, Commercial
Amy Peterson - Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Dana Aftab - Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
Conference Call Participants
Michael Schmidt - Guggenheim
Asthika Goonewardene - Truist
Sean Laaman - Morgan Stanley
Silvan Tuerkcan - Citizens
Yaron Werber - TD Cowen
Chi Fong - Bank of America Securities
Akash Tewari - Jefferies
Eva Fortea-Verdejo - Wells Fargo
Andy Hsieh - William Blair
Eason Lee - Leerink Partners
Cheng Li - Oppenheimer
Ashwani Verma - UBS
Peter Lawson - Barclays
Felix Ampomah - Stephens
Operator
Good day, ladies and gentlemen, and welcome to the Exelixis First Quarter 2025 Financial Results Conference Call. My name is Towanda, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan Hubbard
Thank you, Towanda, and thank you all for joining us for the Exelixis first quarter 2025 financial results conference call.
Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Amy Peterson, our Chief Medical Officer; and Dana Aftab, our Chief Scientific Officer who will review our progress for the first quarter 2025 ended March 31st, 2025.
During the call today, we will refer to financial measures
- Read more current EXEL analysis and news
- View all earnings call transcripts